Welcome to the Stocktwits Top 25 Newsletter for Week 24 of 2024!

The Stocktwits Top 25 reports the 25 best-performing stocks in the S&P 500, Nasdaq 100, and Russell 2000 year to date (YTD) and tracks their performances over time. 

Here are the Stocktwits Top 25 Lists for Week 24:

P.S. To help you understand this data further, check out our FAQ page, and feel free to reach out if you have questions!

The S&P 500 Top 25 list (+4.28%) outperformed the S&P 500 index (+1.58%).

There were 4 major changes to the list this week.

Check out how the momentum meter has performed vs. the S&P 500 index.

This new list from Stocktwits sifts through the noise to discover stocks above $1B market cap with high relative strength and a low social following. In other words, we help you find the strongest trends before your friends. 😉

To join thousands of other traders and investors receiving the latest “Trends With No Friends” in your inbox Sunday through Thursday, click here.

The Nasdaq 100 Top 25 list (+4.16%) outperformed the Nasdaq 100 index (+3.47%).

There were 3 major changes to the list this week.

The Russell 2000 Top 25 list (+4.25%) outperformed the Russell 2000 index (-1.01%).

There were 3 major changes to the list this week.

The Top 25 lists' Top Dawg was Avidity Biosciences, which rallied 49.02%. 📈

The mid-cap biotech stock soared after announcing encouraging initial data from its phase I/II Fortitude study evaluating its treatment of a rare genetic disease of the muscles (facioscapulohumeral muscular dystrophy). 🔬

Based on the results, management plans to accelerate the initiation of registration cohorts in the Fortitude study. The news also caused several analysts to upgrade the stock. 👍

$RNA is up 338.01% YTD.

Follow our social channels for great, real-time content on Stocktwits and Twitter. And check out our YouTube channel for in-depth video content! 📲

Help us deliver the best content possible by completing this brief survey. 📝

Email me (Tom Bruni) your feedback; I’d love to hear from you. 📧

Want to sponsor this newsletter and reach hundreds of thousands of passionate investors and traders? Reach us here. 👍

Disclaimer: Content, news, research, tools, and securities symbols are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here. 🔍